PMC:7344504 / 9142-9808 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T21","span":{"begin":180,"end":184},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma74402"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"250","span":{"begin":160,"end":172},"obj":"Species"},{"id":"251","span":{"begin":218,"end":225},"obj":"Species"},{"id":"252","span":{"begin":365,"end":373},"obj":"Species"},{"id":"253","span":{"begin":598,"end":606},"obj":"Species"},{"id":"254","span":{"begin":28,"end":33},"obj":"Chemical"},{"id":"255","span":{"begin":141,"end":146},"obj":"Chemical"},{"id":"256","span":{"begin":424,"end":429},"obj":"Chemical"},{"id":"257","span":{"begin":638,"end":646},"obj":"Chemical"},{"id":"258","span":{"begin":379,"end":405},"obj":"Disease"},{"id":"259","span":{"begin":190,"end":194},"obj":"Mutation"}],"attributes":[{"id":"A250","pred":"tao:has_database_id","subj":"250","obj":"Tax:746128"},{"id":"A251","pred":"tao:has_database_id","subj":"251","obj":"Tax:9606"},{"id":"A252","pred":"tao:has_database_id","subj":"252","obj":"Tax:9606"},{"id":"A253","pred":"tao:has_database_id","subj":"253","obj":"Tax:9606"},{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"MESH:D001393"},{"id":"A255","pred":"tao:has_database_id","subj":"255","obj":"MESH:D001393"},{"id":"A256","pred":"tao:has_database_id","subj":"256","obj":"MESH:D001393"},{"id":"A257","pred":"tao:has_database_id","subj":"257","obj":"MESH:D014230"},{"id":"A258","pred":"tao:has_database_id","subj":"258","obj":"MESH:D007239"},{"id":"A259","pred":"tao:has_standard_notation","subj":"259","obj":"p.L98H"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T37","span":{"begin":44,"end":48},"obj":"Disease"},{"id":"T38","span":{"begin":395,"end":405},"obj":"Disease"},{"id":"T39","span":{"begin":588,"end":597},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0007163"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T61","span":{"begin":119,"end":120},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T62","span":{"begin":160,"end":161},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T63","span":{"begin":180,"end":184},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T64","span":{"begin":226,"end":229},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T65","span":{"begin":566,"end":569},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T72","span":{"begin":28,"end":33},"obj":"Chemical"},{"id":"T73","span":{"begin":141,"end":146},"obj":"Chemical"},{"id":"T74","span":{"begin":379,"end":384},"obj":"Chemical"},{"id":"T75","span":{"begin":424,"end":429},"obj":"Chemical"},{"id":"T76","span":{"begin":638,"end":646},"obj":"Chemical"}],"attributes":[{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"},{"id":"A73","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"},{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"},{"id":"A75","pred":"chebi_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/CHEBI_68452"},{"id":"A76","pred":"chebi_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/CHEBI_38597"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T80","span":{"begin":0,"end":155},"obj":"Sentence"},{"id":"T81","span":{"begin":156,"end":448},"obj":"Sentence"},{"id":"T82","span":{"begin":449,"end":666},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}

{"project":"2_test","denotations":[{"id":"32517166-24204249-60114387","span":{"begin":291,"end":293},"obj":"24204249"},{"id":"32517166-32297377-60114388","span":{"begin":608,"end":609},"obj":"32297377"},{"id":"32517166-29570855-60114389","span":{"begin":610,"end":612},"obj":"29570855"},{"id":"32517166-28911045-60114390","span":{"begin":659,"end":661},"obj":"28911045"},{"id":"32517166-30580035-60114391","span":{"begin":662,"end":664},"obj":"30580035"}],"text":"We report the first case of azole-resistant CAPA, which occurred in an immunocompetent host during ICU support without a previous history of azole therapy. The A. fumigatus cyp51A gene TR34/L98H mutation found in this patient has been well described as an environmentally acquired mutation [16], which is in line with data from clinical studies where two-thirds of patients with azole-resistant infections had no history of azole pretreatment [10]. This case underscores the importance of early diagnosis and the need for resistance surveillance, comparable to what has been described in influenza patients [9,17], given the emergence of triazole resistance [18,19]."}